Physician profile
Christopher E Belcher
NPI 1407896392
$579,065.64
in general payments reported to CMS, 2019-2025
31 companies · $94K in 2025
The $94K reported for 2025 was more than what 97% of Pediatric Infectious Diseases providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170K · 2020: $53K · 2021: $14K · 2022: $45K · 2023: $112K · 2024: $90K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $210K · Travel and Lodging: $39K · Honoraria: $37K · Consulting Fee: $5,525 · Food and Beverage: $5,433 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,674.00 |
| Travel and Lodging | $39,043.49 |
| Honoraria | $37,282.00 |
| Consulting Fee | $5,525.00 |
| Food and Beverage | $5,433.22 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $189,172.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $125,955.26 | 2019-2025 | Vaxneuvance, Enflonsia, Zerbaxa |
| Parapro, LLC | $103,614.72 | 2019-2024 | Natroba |
| Emergent Biosolutions INC. | $57,854.22 | 2019 | |
| Sobi, INC | $57,373.23 | 2019-2021 | |
| Pfizer INC. | $43,561.20 | 2023-2024 | |
| La Jolla Pharmaceutical Company | $347.61 | 2021-2025 | Zevtera, Xacduro |
| Paratek Pharmaceuticals, INC. | $162.00 | 2019-2025 | Nuzyra |
| Abbvie INC. | $128.46 | 2019-2024 | Dalvance |
| Melinta Therapeutics, LLC | $108.91 | 2019 | |
| Glaxosmithkline, LLC. | $75.45 | 2025 | Bexsero |
| Valneva USA, INC. | $61.52 | 2023-2025 | Ixchiq |
| Csl Behring | $58.14 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $55.00 | 2019 | |
| Astellas Pharma US INC | $53.22 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $51.94 | 2019 | |
| Theratechnologies INC. | $47.02 | 2019 | |
| Viiv Healthcare Company | $45.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.00 | 2020 | |
| Janssen Biotech, INC. | $40.58 | 2019 | |
| Napo Pharmaceuticals INC | $34.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $33.72 | 2019 | |
| Horizon Therapeutics Plc | $31.09 | 2019 | |
| Insmed, INC. | $30.16 | 2019 | |
| Allergan, INC. | $27.80 | 2019-2020 | |
| Pharming Healthcare, INC. | $26.00 | 2022 | |
| Tactile Systems Technology INC | $25.50 | 2019 | |
| Emd Serono, INC. | $14.13 | 2019 | |
| Gilead Sciences, INC. | $13.28 | 2019 | |
| Daiichi Sankyo INC. | $11.26 | 2019 | |
| Shire North American Group INC | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Belcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.